新“药王”诞生!K药挣扎,艾伯维、赛诺菲自免霸主争夺战开启

华尔街见闻
21 Dec 2024

伴随2024年接近尾声,全球畅销药榜单备受业界期待。 近日,Nature杂志官网上刊登的一篇报告揭晓了答案。如果从单药销售额角度,有望达到310亿美元年销售额的K药自然继续卫冕,但如果统计司美格鲁肽整体销售额,根据该报告预测,降糖版Ozempic和减重版Wegovy加起来就已经达到了356亿美元。K药仅坐了1年的“药王”宝座,就无奈让出。 眼看K药第一宝座危矣,默沙东寻下一超级重磅炸弹的决心极猛。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10